Anti-Human GM-CSF R alpha Reference Antibody (Mavrilimumab, RUO)

Description: Mavrilimumab (BS10169) is a research-grade recombinant antibody targeting CD116. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG4-lambda2
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD116,CSF2R,GMR-alpha,CSF2RA,Granulocyte-macrophagecolony-stimulatingfactorreceptorsubunitalpha,CSF2RY,GMCSFR-alpha,GM-CSF-R-alpha,CDw116
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CAM-3001,CAS:1085337-57-0
Background: Granulocyte-macrophage colony-stimulating factor receptor subunit alpha (CD116/CSF2RA) is a ~46 kDa protein. Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells.
Note: For research use only. Not suitable for clinical or therapeutic use.